Key Takeaways
- • Spire Healthcare agreed to a £1.03bn take-private acquisition by Tulip UK Bidco, a consortium comprising Toscafund, THCP Advisory, and Ares, at 250p per share—a 66% premium to the share price at the beginning of May 2026.
- • The transaction values Spire at an enterprise value of £2.31bn, with completion expected by early 2027, and represents a strategic exit for the London-listed private hospital operator that has faced share price volatility since its July 2014 IPO.
- • Long-serving Chief Executive Justin Ash and Chairman Sir Ian Cheshire are stepping down as the company transitions to new ownership; Sir David Sloman (former NHS trust leader) assumes interim CEO role, with former Co-op Chair Debbie White taking interim chair position.
- • The consortium justified the acquisition by highlighting that Spire's freehold property assets are undervalued in the public markets and that taking the company private will unlock strategic and financial flexibility for long-term value creation.
- • Spire operates 38 private hospitals previously owned by Bupa and has evolved into an integrated healthcare company, though the board determined public market valuations did not fairly reflect the company's growth prospects or asset base.
Summary
Spire Healthcare, the London-listed private hospital operator, has agreed to be acquired for £1.03bn by Tulip UK Bidco, a newly formed consortium of British investment firm Toscafund, UK private equity firm THCP Advisory, and California-based investment manager Ares. The 250p-per-share cash offer represents a 66% premium to Spire's share price in early May 2026, when Toscafund initially approached the company. The transaction values Spire at an enterprise value of £2.31bn and is expected to complete by early 2027.
The consortium's rationale centers on unlocking value from Spire's significant freehold property portfolio, which the bidders assert is not adequately reflected in the company's public market valuation. In announcing the deal, Tulip UK Bidco stated that taking Spire private "would provide strategic and financial flexibility to unlock long-term stakeholder value." Spire's board supported the acquisition, citing concerns that the company's share price could face prolonged volatility and did not fairly represent its growth trajectory. Since the July 2014 IPO, Spire shares had closed at 242p on the announcement date, up only 15% from listing price despite the company evolving from a hospital-only business into a leading integrated healthcare provider operating 38 private hospitals (formerly owned by Bupa).
Leadership transitions accompany the take-private process. Long-serving Chief Executive Justin Ash is retiring as the company "enters a new phase with strong foundations" under its new owners, while Chairman Sir Ian Cheshire will also step down. Sir David Sloman, who has held senior leadership roles at multiple NHS trusts, will serve as interim chief executive, and Debbie White, the former Co-op chair, will assume the interim chair position. The board cited Ash's stewardship in transforming Spire into an integrated healthcare company under his leadership.
The consortium's rationale centers on unlocking value from Spire's significant freehold property portfolio, which the bidders assert is not adequately reflected in the company's public market valuation. In announcing the deal, Tulip UK Bidco stated that taking Spire private "would provide strategic and financial flexibility to unlock long-term stakeholder value." Spire's board supported the acquisition, citing concerns that the company's share price could face prolonged volatility and did not fairly represent its growth trajectory. Since the July 2014 IPO, Spire shares had closed at 242p on the announcement date, up only 15% from listing price despite the company evolving from a hospital-only business into a leading integrated healthcare provider operating 38 private hospitals (formerly owned by Bupa).
Leadership transitions accompany the take-private process. Long-serving Chief Executive Justin Ash is retiring as the company "enters a new phase with strong foundations" under its new owners, while Chairman Sir Ian Cheshire will also step down. Sir David Sloman, who has held senior leadership roles at multiple NHS trusts, will serve as interim chief executive, and Debbie White, the former Co-op chair, will assume the interim chair position. The board cited Ash's stewardship in transforming Spire into an integrated healthcare company under his leadership.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.